Centre for Probe Development and Commercialization Products Recall (2019-04-17)
- Starting date:
- April 17, 2019
- Type of communication:
- Drug Recall
- Subcategory:
- Drugs
- Hazard classification:
- Type III
- Source of recall:
- Health Canada
- Issue:
- Product Safety
- Audience:
- General Public, Healthcare Professionals, Hospitals
- Identification number:
- RA-69766
Last updated: 2019-04-30
Summary
-
Product:
A. Glucovision (Phosphate) 540 GBQ / Vial solutionB. Glucovision (Citrate) 453 GBQ / Vial solution
A. Glucovision (Phosphate) 540 GBQ / Vial solution
B. Glucovision (Citrate) 453 GBQ / Vial solution
Reason
Affected lots may contain particulate matter.
Depth of distribution
Healthcare establishments, End users
Affected products
A. Glucovision (Phosphate) 540 GBQ / Vial solution
DIN, NPN, DIN-HIM
DIN 02486652
Dosage form
Solution
Strength
Fludeoxyglucose 18F 540 GBQ/vial
Lot or serial number
T-190417FDG-2
Companies
- Recalling Firm
-
Centre for Probe Development and Commercialization (CPDC)
1280 Main St. W. NRB-A316
Hamilton
L8S 4K1
Ontario
CANADA
- Marketing Authorization Holder
-
Centre for Probe Development and Commercialization (CPDC)
1280 Main St. W. NRB-A316
Hamilton
L8S 4K1
Ontario
CANADA
B. Glucovision (Citrate) 453 GBQ / Vial solution
DIN, NPN, DIN-HIM
DIN 02328771
Dosage form
Solution
Strength
Fludeoxyglucose 18F 453 GBQ/vial
Lot or serial number
T-190417FDG-1
Companies
- Recalling Firm
-
Centre for Probe Development and Commercialization (CPDC)
1280 Main St. W. NRB-A316
Hamilton
L8S 4K1
Ontario
CANADA
- Marketing Authorization Holder
-
Centre for Probe Development and Commercialization (CPDC)
1280 Main St. W. NRB-A316
Hamilton
L8S 4K1
Ontario
CANADA